GFGuillermo Fernández-Conejo

Guillermo Fernández-Conejo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillermo Fernández-Conejo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective Comparison of Two Robotic Platforms for the Performance of Radical Prostatectomy: Versius vs. DaVinci

    by Sara Garach Fernández, Silvia García Barreras, Gema Martín Serrano, Guillermo Fernández Conejo, Francisco Javier Burgos Revilla

    Background/Objectives: To compare the perioperative, oncological and functional outcomes of the Versius® and DaVinci® systems as used for performing robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer. Methods: Prospective observational comparative study on 278 patients subjected to RARP between March 2023-September 2025. 169 procedures were performed with the Versius® system and 109 with the DaVinci® system. An analysis was performed of a series of demographic, perioperative, pathological and functional variables. Quantitative variables were compared using either Student’s t or the Mann-Whitney Test, while categorical variables were analyzed with the chi-squared test or Fisher’s Exact Test. Results: Both groups exhibited comparable baseline characteristics. No statistically significant differences were observed with respect to the amount of pelvic lymph nodes dissected, intraoperative or postoperative complications, transfusion requirements, length of hospital stay or postoperative PSA levels. DaVinci® was shown to be associated with higher rates of neurovascular bundle preservation (48.6% vs. 17.4%; p< 0.001) and the resection of a higher number of positive lymph nodes. Patients operated with the DaVinci® system were more likely to have pN1 disease (20% vs. 4.9%; p=0.014). No statistically significant differences were observed with respect to positive surgical margins, pT stage or the ISUP grade of the specimen. Urinary incontinence was more prevalent in the Versius® group at 3 and 6 months’ follow-up (p=0.003 y p=0.034, respectively), without significant differences at 12 months. Conclusions: Both Versius® and DaVinci® were shown to be safe and effective platforms for the performance of RARP, with comparable short-term perioperative and oncological outcomes.

  • Open Access

    Learning curve of Versius‐assisted radical prostatectomy: role of prior experience and proctoring

    by Guillermo Fernández‐Conejo, Claudia González Álvarez, Pedro Del Olmo Durán, Ana Tagalos Muñoz, Enrique Sanz Mayayo, Víctor Diez Nicolás, Silvia García Barreras, Jose Daniel Subiela Henríquez, Rafael Rodríguez‐Patrón, Elia Pérez‐Fernández, et al.

    Objective: To assess the learning curve for radical prostatectomy (RP) with the Versius system (CMR Surgical, Cambridge, UK) and evaluate the transfer of skills from previous robotic and laparoscopic practice. Subjects, Patients and Methods: This prospective cohort study included patients with localised prostate cancer undergoing Versius‐assisted RP. Four surgeons participated: two with extensive prior robotic experience (>500 Da Vinci Surgical System [Intuitive Surgical Inc., Sunnyvale, CA, USA] RPs) and two with laparoscopic but no robotic background, operating under structured proctoring. Outcomes included objective measures such as console time or novel hand motion volumetry. Proficiency was defined by Learning Curve Cumulative Sum (LC‐CUSUM) analysis with thresholds of console time <165/180 min (without/with lymphadenectomy) and absence of significant positive surgical margins. Results: A total of 151 consecutive patients were included. Pre‐ and postoperative characteristics were comparable across surgeons. There were clinically and statistically significant improvements in operative time and hand motion metrics with increasing experience. Proficiency was achieved after 23 cases by experienced surgeons and after 37 by novel surgeons. The overall positive margin rate was 27.8%, with only two cases exceeding the ≥3 mm threshold in nerve‐sparing procedures. Major complications (Clavien–Dindo Grade ≥III) only occurred in four (2.6%) patients. Conclusion: Surgical proficiency in Versius‐assisted RP was achieved in <40 cases, particularly among surgeons with prior robotic experience. Structured proctoring shortened the learning curve, and hand motion volumetry emerged as an objective marker of skill, supporting its use in training and competency assessment.


  • Standardizing radical prostatectomy with the Versius robotic system: technical setup and early institutional experience

    by Guillermo Fernández-Conejo, Jose Daniel Subiela Henríquez, Ana Tagalos Muñoz, Claudia González Álvarez, Ana Fernández Mardomingo, Enrique Sanz Mayayo, Víctor Díez Nicolás, Silvia García Barreras, Victoria Gómez Dos Santos, Rafael Rodríguez-Patrón, et al.

    Robot-assisted radical prostatectomy (RARP) is the gold standard for localized prostate cancer, but the high cost of robotic systems limits adoption. The Versius robotic system, approved in 2018, offers a cost-effective alternative with modular design and ergonomic benefits. This study evaluates its technical setup, intraoperative performance, and early institutional experience with RARP. A detailed description of all the elements and the optimal setup for radical prostatectomy in order to minimize issues or clashes between arms and to improve the beginning of a Versius robot program in other centers. A descriptive analysis of 135 patients undergoing RARP using the Versius system was conducted between May 2023 and February 2025. Four urologists, two with prior robotic surgery experience and two beginners, performed the procedures. An optimal setup of the robot does RARP feasible with the Versius robot system, with competitive times of surgery. Limitations include the study's single-center design and the novelty of the Versius system in this setting, this makes necessary this type of studies by developing the setup and critical points of a new robotic system. The Versius robotic system is promising for RARP, offering ergonomic benefits and efficient surgical workflows. While early results are encouraging, further studies are needed to refine its setup and optimize use for broader clinical adoption.


  • Outcomes of an enhanced recovery after radical cystectomy program in a prospective multicenter study: compliance and key components for success

    by C. Llorente, A. Guijarro, V. Hernández, G. Fernández-Conejo, J. Passas, L. Aguilar, A. Tejido, C. Hernández, M. Moralejo, D. Subirá, et al.

    Objective To investigate the effect of an Enhanced Recovery After Surgery (ERAS) program on complications and length of stay (LOS) after radical cystectomy (RC) and to assess if the number and type of components of ERAS play a key role on the decrease of surgical morbidity. Materials and methods We analyzed the data of 277 patients prospectively recruited in 11 hospitals undergoing RC initially managed according to local practice (Group I) and later within an ERAS program (Group II). Two main outcomes were defined: 90-day complications rate and LOS. As secondary variables we studied 90-day mortality, 30-day readmission and transfusion rate. Results Patients in Group II had a higher use of ERAS measures (98.6%) than those in Group I (78.2%) (p < 0.05). Patients in Groups I and II experienced similar complications (70.5% vs. 66%, p = 0.42). LOS was not different between Groups I and II (12.5 and 14 days, respectively, p = 0.59). The risk of having any complication decreases for patients having more than 15 ERAS measures adopted [RR = 0.815; 95% confidence interval (CI) 0.667–0.996; p = 0.045]. Avoidance of transfusion and nasogastric tube, prevention of ileus, early ambulation and a fast uptake of a regular diet are independently associated with the absence of complications. Conclusions Complications and LOS after RC were not modified by the introduction of an ERAS program. We hypothesize that at least 15 measures should be applied to maximize the benefit of ERAS


  • The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer

    by Guillermo Fernández-Conejo, Enrique de la Peña, Virginia Hernández, Ana Guijarro, Alejandro Castro, Elia Pérez-Fernández, Carlos Llorente

    Objective: To further assess the influence of the weight after TURBT as a predictive factor for recurrence and progression in NMIBC. Materials and methods: A cohort of patients with a first episode of NMIBC between 1999 and 2016 was analysed retrospectively. We studied the correlation between the tumour’s size and weight, the time-dependent ROC curves for the optimal weight value for the prediction of recurrence and progression and their association with the risk of recurrence and progression at one and five years. Results: We analysed 470 patients who met inclusion criteria. Median (IQR) follow-up time was four years (2.2–6.7), 227 (48.3%) patients had a recurrence and 46 (9.8%) progressed. Median (IQR) weight after resection was 2 g (0.8–6) and its correlation with size was 0.56. The optimal value for the prediction of recurrence was 4 g. The RFS at one and five years with a weight p < .001). PFS at one and five years was 98% and 92.7% for a weight 4 g, respectively (p = .02). On multivariate analysis, a higher weight was associated with an increased risk of recurrence: HR [95%:CI] = 1.52[1.05–1.86], and progression: HR[95%:CI] = 1.87[1.01–3.47] (p < .05). Conclusion: The weight of the specimen obtained after TURBT is a predictive factor of both recurrence and progression in NMIBC that may be more accurate than tumour size and easily and objectively measured. An increase of 52% and 87% in the risk of recurrence and progression, respectively, was found in tumours weighing more than 4 g.


  • Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long‐term follow‐up series

    by Guillermo Fernández‐Conejo, Virginia Hernández, Ana Guijarro, Enrique de la Peña, Alberto Inés, Elia Pérez‐Fernández, Carlos Llorente

    Background: Active surveillance (AS) has become a valid option for patients with a very low risk of prostate cancer (PC) with a widespread application. There are still a few series, with a medium follow‐up longer than 5 years, reporting data on pathological upgrading. The objective is to evaluate the changes in surveillance biopsies of patients with low‐risk PC in a long‐term follow‐up and determine if a longer stay in AS could involve worse pathological findings.Materials and Methods: A retrospective analysis of our institutional database of patients with PC undergoing AS during 2004 to 2018 was performed. The inclusion criteria were prostate‐specific antigen (PSA) ≤ 10 ng/mL, Gleason grade 1 and T1c/T2a. Patients were assessed by serum PSA level and digital rectal examination at 6‐month intervals. Transrectal ultrasound‐guided prostate biopsies were performed during the first year of follow‐up, and every 2 or 3 years thereafter. The pathology details of biopsies were analyzed and compared with the current series on AS.Results: Three‐hundred nineteen patients undergoing AS were evaluated with a median follow‐up of 5.3 years and a mean age of 67.4 years. Sixty‐three patients did not meet all the criteria to be considered low‐risk PC but were included in the analysis. Overall, 128 patients (40.1%) underwent active treatment (84.7% of them due to pathological progression in surveillance biopsies). The proportion of patients with a reported upgrading ranged between 19.4% and 35.3%, although only the fourth biopsy showed an upgrading proportion of over 30%. Limitations include the retrospective design of the study and the existence of different protocols between other cohorts that make it difficult to compare their results.Conclusions: For patients who remained in surveillance the percentage of upgrading increased slightly with the time, being more frequent after the third‐surveillance biopsy. These findings support the importance of extending surveillance biopsies for patients who remain candidates for curative treatment.


    • 1 November 2019
      • Vol. 72  (9) , 915-920

    Incidence and prognosis of clinically significant incidental prostate cancer after radical cystectomy for bladder cancer

    by Guillermo Fernandez-Conejo, Enrique de la Pena, Virginia Hernandez, Alejandro Castro, Elia Perez-Fernandez, Carlos Llorente

    OBJECTIVE: To evaluate the prevalence and significance of incidental prostate cancer in patients after radical cystectomy for bladder cancer, as well as its impact in terms of overall survival and biochemical recurrence. METHODS: Patients with bladder cancer treated with radical cystectomy in our hospital between 1998 and 2014 were included in the study. None of the patients had previous history of prostatic adenocarcinoma. Complete embedding of the prostate gland as whole mount serial section of the radical cystectomy specimens was done. RESULTS: 180 patients were included. The mean age was 69.71 years with a median follow-up of 34.2 months. Three groups were analyzed: non-incidental prostate cancer (n=136), non-significant incidental prostate cancer (n=28) and significant incidental prostate cancer (n= 16). During follow-up, 50 patients (27.78%) died from bladder cancer. There were no differences in overall survival between patients with or without prostate cancer, neither between patients with significant nor insignificant prostate cancer in the radical cystectomy specimens. Biochemical recurrence was not observed in any patient. CONCLUSIONS: Incidental prostate cancer had a higher prevalence than previously expected in our cohort (24.4%), but it had no impact in overall survival of patients not even in those with a significant prostate cancer. No biochemical recurrence was reported during the study.


    • 1 September 2019
      • Vol. 72  (7) , 709-712

    Complicated renal cyst by fistula from acute appendicitis on an appendicular mucocele. First literature report

    by Guillermo Fernandez-Conejo, Jose Manuel de la Morena, Ignacio Sola, Pedro Jimenez-Almonacid, Libertad Martin, Grevelyn Sosa, Carlos Llorente

    We describe the first clinical case in the reviewed literature of a patient with a complicated renal cyst by fistula of an appendicular neoplasm with acute appendicitis, as well as the management performed and the therapeutic options in similar cases.